TCGA-34-5928-01A-11R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 83
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.660
- ANGIOGENESIS+0.580
- HEDGEHOG_SIGNALING+0.470
- TGF_BETA_SIGNALING+0.420
- UV_RESPONSE_DN+0.380
- WNT_BETA_CATENIN_SIGNALING+0.360
- APICAL_JUNCTION+0.350
- HYPOXIA+0.330
- PROTEIN_SECRETION+0.330
- TNFA_SIGNALING_VIA_NFKB+0.330
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- OXIDATIVE_PHOSPHORYLATION-0.280
- DNA_REPAIR-0.180
- BILE_ACID_METABOLISM-0.170
- E2F_TARGETS-0.170
- XENOBIOTIC_METABOLISM-0.120
- HEME_METABOLISM-0.110
- PEROXISOME-0.100
- ADIPOGENESIS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.881 |
| 2 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.859 |
| 3 | TCGA-EW-A1PG-01A-11R-A144-07 | — | A | 0.842 |
| 4 | TCGA-43-6647-01A-11R-1820-07 | — | cohortSQ1 | 0.837 |
| 5 | TCGA-77-8138-01A-11R-2247-07 | — | cohortSQ1 | 0.827 |
| 6 | TCGA-98-8020-01A-11R-2247-07 | — | cohortSQ1 | 0.823 |
| 7 | MDT-AP-3275 | Med | Medulloblastoma | 0.821 |
| 8 | TCGA-85-8481-01A-11R-2326-07 | — | cohortSQ1 | 0.816 |
| 9 | TCGA-43-6771-01A-11R-1820-07 | — | cohortSQ1 | 0.812 |
| 10 | TCGA-85-8353-01A-21R-2296-07 | — | cohortSQ1 | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.660 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |